nosis. 1 GS after allogeneic BMT for leukemia is quite rare and predicts an additional hazard to outcome after BMT. 2 We here report a patient who relapsed with locally In 1988, a 27-year-old male patient received an allogeneic BMT for leukemic relapse 8 months after ABMT advanced gastrointestinal GS more than 7 years after allogeneic BMT for AML and who received donor buffy coat for AML (M2) in first complete remission. Because of chronic GVHD of the liver CsA was administered until transfusions in addition to polychemotherapy, local irradiation and surgery. 1994. Nine months after discontinuation of CsA, locally advanced gastric granulocytic sarcoma (GS) was diagnosed without evidence of systemic relapse. The patient was treated with two courses of polychemotherapy Case report (ICE, NOVIA). Granulocyte colony-stimulating factor (G-CSF)-mobilized donor buffy coat cells were rein-AML (M2) was first diagnosed in December 1986 in a 25-year-old male patient. ABMT was performed in first comfused after each chemotherapy cycle in an attempt to accelerate hematopoietic regeneration and to induce a plete remission in June 1987 using CY/fTBI as the pretransplant conditioning regimen. However, 6 months later graft-versus-leukemia (GVL) effect. Local irradiation and surgical resection of residual leukemic cells resulted the patient relapsed and an allogeneic BMT with his previously unavailable, HLA-identical, MLC non-reactive sisin complete remission. Seventeen months from diagnosis of GS the patient relapsed again with multiple lesions ter as bone marrow donor was performed in March 1988 without prior remission induction. BuCY was used as the and died of generalized bleeding during aplasia after a third course of polychemotherapy (ICE). In our patient conditioning regimen and GVHD prophylaxis consisted of CsA/MTX according to the Seattle protocol. 3 Acute GVHD donor peripheral blood stem cell support did not accelerate hematopoietic regeneration (time to neutrophil of the skin, overall grade 1, was diagnosed on day +27, but did not require further immunosuppression. Because of recovery Ͼ0.5 × 10 9 g/l from the start of chemotherapy was 27 days after ICE and 36 days after NOVIA) and histologically proven chronic liver GVHD at 6 months and 2 years after the allogeneic BMT, CsA treatment was maindid not result in long-term disease-free survival.
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We here report a patient who relapsed with locally In 1988, a 27-year-old male patient received an allogeneic BMT for leukemic relapse 8 months after ABMT advanced gastrointestinal GS more than 7 years after allogeneic BMT for AML and who received donor buffy coat for AML (M2) in first complete remission. Because of chronic GVHD of the liver CsA was administered until transfusions in addition to polychemotherapy, local irradiation and surgery. 1994. Nine months after discontinuation of CsA, locally advanced gastric granulocytic sarcoma (GS) was diagnosed without evidence of systemic relapse. The patient was treated with two courses of polychemotherapy Case report (ICE, NOVIA). Granulocyte colony-stimulating factor (G-CSF)-mobilized donor buffy coat cells were rein-AML (M2) was first diagnosed in December 1986 in a 25-year-old male patient. ABMT was performed in first comfused after each chemotherapy cycle in an attempt to accelerate hematopoietic regeneration and to induce a plete remission in June 1987 using CY/fTBI as the pretransplant conditioning regimen. However, 6 months later graft-versus-leukemia (GVL) effect. Local irradiation and surgical resection of residual leukemic cells resulted the patient relapsed and an allogeneic BMT with his previously unavailable, HLA-identical, MLC non-reactive sisin complete remission. Seventeen months from diagnosis of GS the patient relapsed again with multiple lesions ter as bone marrow donor was performed in March 1988 without prior remission induction. BuCY was used as the and died of generalized bleeding during aplasia after a third course of polychemotherapy (ICE). In our patient conditioning regimen and GVHD prophylaxis consisted of CsA/MTX according to the Seattle protocol. 3 Acute GVHD donor peripheral blood stem cell support did not accelerate hematopoietic regeneration (time to neutrophil of the skin, overall grade 1, was diagnosed on day +27, but did not require further immunosuppression. Because of recovery Ͼ0.5 × 10 9 g/l from the start of chemotherapy was 27 days after ICE and 36 days after NOVIA) and histologically proven chronic liver GVHD at 6 months and 2 years after the allogeneic BMT, CsA treatment was maindid not result in long-term disease-free survival. Keywords: granulocytic sarcoma; allogeneic bone martained until September 1994. In July 1995, the patient presented with upper abdominal row transplantation; donor buffy coat transfusion; graftversus-leukemia (GVL) effect pain, weight and appetite loss, dysphagia, fatigue and a palpable epigastric mass. A large, green-colored ulcer on the greater curvature was identified by endoscopy. Biopsies revealed a monotonous infiltrate of CD34 + , myeloperoxidGranulocytic sarcomas (GS) are rare but well-recognized ase-positive immature myeloid cells. Gastric GS was diagextramedullary manifestations of AML. The incidence of nosed without evidence of medullary relapse, determined primary GS varies widely from 3% in retrospective analyby bone marrow examination including cytogenetics, comses up to 30% in patients with acute monocytic leukemia. puted tomography and gallium scintigraphy. Complete Sites of involvement include virtually any body site with a chimerism was also confirmed by cytogenetics and the host predilection for the skin, lymph nodes, spine, and small origin of tumor cells was determined by fluorescence in intestine. Isolated extramedullary recurrence of AML gensitu hybridization (FISH) using an XY-specific probe erally heralds bone marrow relapse and has a poor prog-(CEPXSO/CEPYSG; Vysis, Framingham, MA, USA). Because of inoperability of the tumor with infiltration of regional lymph nodes and the celiac trunk, the patient was NOVIA (mitoxantrone, cytarabine) as consolidation. After sion after buffy coat infusion is unknown, and remains to be seen. In line with a recently published non-randomized each cycle (48 h after the last dose of chemotherapy), G-CSF-mobilized (10 g/kg/day for 4 consecutive days) study, 11 peripheral blood stem cell support seems not to be effective in accelerating hematopoietic recovery from donor buffy coat cells were reinfused without GVHD prophylaxis (total nucleated cell dose given was 12.7 × 10 8 salvage chemotherapy, although our experience is now limited to the patient reported and another patient receiving cells/kg body weight). Time to neutrophil recovery (Ͼ0.5 × 10 9 g/l) from the first day of chemotherapy was 27 this protocol. In both patients time to neutrophil recovery was similar to that of newly diagnosed AML patients days after ICE and 36 days after NOVIA. Four weeks after the end of involved field irradiation (30 Gy), which was receiving ICE or NOVIA at our institution, but results of the EORTC-GIMEMA AML 10 trial, in terms of hematostarted after hematological recovery, the initially involved gastric wall and a small, residual leukemic lesion (diameter poietic recovery after ICE or NOVIA, have not yet been published. Ͻ1 cm) in the ligamentum gastrocolicum were surgically resected resulting in complete remission determined by Experience with donor buffy coat infusions in patients relapsing with GS after allogeneic BMT for AML is limited endoscopy and computed tomography. Neither acute nor chronic GVHD developed after buffy coat infusion. Sevento one patient reported in the EBMT analysis. 2 This patient received donor lymphocytes in combination with local teen months after the initial diagnosis of GS the patient presented again with multiple lesions and multiple organ irradiation for multiple GS lesions resulting in complete remission for more than 50 months after diagnosis of GS. involvement. He opted for further treatment and received an additional course of ICE followed by an additional GIn our patient, salvage chemotherapy to reduce tumor burden prior to G-CSF-mobilized donor lymphocyte trans-CSF-mobilized donor buffy coat infusion (total nucleated cell dose given was 3.7 × 10 8 cells/kg body weight), but the fusion, although producing remission in combination with local irradiation and excision surgery, did not result in longpatient finally died of generalized bleeding during aplasia.
term disease-free survival. A study protocol evaluating the impact of donor lymphocyte transfusion after tumorreducing remission induction chemotherapy prior to a Discussion retransplant with allogeneic peripheral blood stem cells in leukemia patients relapsing after BMT is currently in Our patient experienced GS more than 7 years after allogeneic BMT for AML. It is very likely that the long-term preparation (Prof A Gratwohl, Basel, Switzerland, personal communication). disease-free survival after allogeneic BMT resulted as much from the antileukemic drug dose applied with the second BMT conditioning regimen as from a GVL effect of donor lymphocytes. There is a close association of GVL with Acknowledgements GVHD, such that patients with either acute or chronic GVHD experience a significant lower relapse incidence. of limited chronic GVHD, although associated with favorable outcome after second BMT, 5 probably hampered complete elimination of residual leukemic cells in our patient and enabled evolution of GS even after CsA treatment had References been stopped. Intensified or prolonged immunosuppression after allogeneic BMT is invariably accompanied by an 
